Triple-negative breast cancer requires precise terminology and current clinical information. Stage, PD-L1 status, germline findings, prior treatment and response can materially change the discussion, especially with recurrent or metastatic TNBC.
CARE ACROSS THE CANCER JOURNEY
Sunridge treats patients at every stage of cancer—including recurrent cancer.
Many patients contact Sunridge after previous treatment because their cancer has returned or progressed. Our physicians take another careful look at the current disease, prior treatment and response, pathology, biomarkers, immune function and overall health before discussing treatment options that may be appropriate. When clinically relevant, this evaluation may include specialized immune-function laboratory testing and testing for environmental or chemical exposures. Sunridge also offers physician-directed cancer-risk assessment, prevention planning and genetic testing.
Recently diagnosedClarify the diagnosis, stage and decisions ahead.
During treatmentReview coordinated supportive-care options and changing needs.
Recurrent, advanced or stage 4Reassess prior treatment, response, current disease and available next steps.
Risk and preventionDiscuss family history, inherited risk and clinically appropriate genetic testing.
20,000+patients served across Sunridge history
Thousandsof treatments administered each year
Onsitephysicians, nurses and dedicated treatment rooms
Worldwidepatients travel to Scottsdale for care
★★★★★
“The entire office staff is 5 stars incredible, kind, hospitable, comfortable and more!”
★★★★★
“From the moment we walked in, the entire staff—from the front desk to the nurses—was incredibly friendly, supportive, and professional.”
★★★★★
“From the moment we walked in, we were treated like VIP clients. Dr. Franco is very knowledgeable.”
These are individual patient experiences. Results vary, and testimonials do not predict or guarantee outcomes for another person.
Explore patient experiences →A MORE USEFUL FIRST REVIEW
Information that can shape the TNBC conversation
Confirmed pathology
Receptor testing, grade and pathology review establish exactly what is being treated.
Biomarker context
PD-L1, germline findings and other clinically relevant results may affect standard treatment discussions.
Response over time
What has already been tried—and how the cancer responded—matters when reviewing the next decision.
